25Nov

OGT continues move into molecular diagnostics markets with MDSAP certification

Oxford, UK – 19 November 2019. Oxford Gene Technology (OGT), A Sysmex Group Company, is proud to announce that its new facility in Cambridge, UK, has achieved Medical Device Single Audit Program (MDSAP) certification of its quality management system (QMS). The announcement further solidifies the company’s aim to reach into molecular diagnostic markets following its first FDA clearance for eight Cytocell Aquarius® Haematology fluorescence in situ hybridisation (FISH) probes earlier this year.
Developed by the International Medical Device Regulators Forum (IMDRF), the MDSAP enables medical device manufacturers to fulfil the requirements of multiple participating regulatory authorities through a single QMS audit.
The certification from Lloyd’s Register (LR) is for the full MDSAP scope, which is based on ISO 13485:2016 with additional country-specific requirements for the US FDA, Health Canada, TGA (Australia), ANVISA (Brazil), MHLW and PMDA (Japan).
John Anson, OGT’s CEO said: “This is a major achievement for the company and clearly further demonstrates our commitment to quality on a global level. MDSAP is a challenging process and its achievement represents a huge team effort across all functions. It demonstrates to our customers that we are dedicated to providing the highest quality molecular diagnostic products and this certification will ultimately facilitate future IVD approvals - bringing these products to market faster.”
John Perkins, Cytocell’s QC/QA Manager, said: “MDSAP certification is yet another important milestone for us, following last year’s successful transition to the updated standards, ISO 9001:2015 and ISO 13485:2016. It demonstrates the strength of our quality system and our continued commitment to quality, in fact in October 2019 we will have held ISO certification continuously for 20 years.”
For more information please visit www.ogt.com.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

Related

Diabetes Research Unit Cymru confirms EKF POCT HbA1c testing comparable to lab-based HPLC

Cardiff, UK – 21st June 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces...

Read More >

EKF POC HbA1c analyzer demonstrates excellent performance in international evaluation study

Quo-Lab meets strict international quality targets – confirming it fit for purpose for diabetes tes...

Read More >

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC

New molecular assay enables rapid antibiotic resistance result to support use of cost effective and ...

Read More >

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI Solutions (BBI) has announced the addition of over 80 new antibodies to its growing product port...

Read More >

RPS Diagnostics partners with Atomo Diagnostics to develop next generation Febridx blood tests for Antibiotic Stewardship in the Outpatient setting

Sarasota, Florida and Sydney, Australia (February 20, 2018) – United States biotechnology company, ...

Read More >

Sensitive, Reliable and Rapid Detection of Cryptococcal Infection

The IMMY CrAg® LFA (Cryptococcal Antigen Lateral Flow Assay) is the first and only immunochromatogra...

Read More >